Psychedelic Spotlight News

  • MindMed’s Jr Rahn On Restructuring How We Treat Mental Health (And why he founded MindMed)

    Listen, Videos

    Today’s episode for you focuses on why C-O FOUNDER and CEO JR Rahn founded Mindmed and on Reconstructing how we treat mental health in America.

    MindMed, (MMED) on the Canadian NEO Stock exchange and (MMEDF) on the American Over the counter market has been experiencing a pull back lately. Remember what I said before: MindMed should be looked as a long term investment and is not for investors with weak stomachs!

    During his recent appearance on Context 360 with Kevin O’Leary, MindMed’s Co-Ceo Jr Rahn made a sober prediction that the mental health crisis will only get worse.
    -automation, sped up by the Rona virus, will depend our crisis of identity, and cause millions more to suffer. If we do nothing now, soon we could be living in a very dark world
    -to reiterate a couple alarming stats; 40% have has a mental health incident or have addiction and 11% have considered committing suicide. This is terrifying, and only going to get worse. MindMed was founded with the vision to find a solution or rather multiple solutions to these mental problems. If successful, the company stands to take the biotech industry by storm and we, as psychedelic investors, will reap the returns.

    https://www.youtube.com/watch?v=mNfq6eEUT7Q&t=459s&ab_channel=ContextLive

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF

  • How Risky is MindMed Stock? (MMED / MMEDF Risk Assessment)

    Listen, Videos

    Today, we have a different episode for you..Usually we talk about all the things I am excited for when it comes to MindMed and MindMed stock, but today, we will visit the darker side by discussing how risky is the MindMed stock.
    It is important for all psychedelic investors to grasp that MindMed is not a sure deal. Yes, I believe that long term it will succeed, but there are certain things that could go wrong.

    We will cover the very real risks involved in investing in MindMed such as:
    1. The possibility of MindMed’s medicines being inefficacious
    – Whether of not MMED’s clinical trials succeed
    2.MindMed’s incertain long term profitability
    – Can the company scale production and training protocols?
    3.MindMed Stock volatility
    – MindMed’s market cap
    – Future short interests

    MindMed trades on the Canadian NEO Market as (MMED) and American OTC market as (MMEDF)

    MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/wp-content/uploads/2020/11/end-of-year-2019-discussion.pdf

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own

  • Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines)

    Listen, Videos

    What’s up Psychedelic Investors? In today’s episode entitled :Important Correction for MindMed Trials (Plus Changes In MMED/MMEDF’S Timelines), we discuss a correction I have to make to my MindMed (MMED / MMEDF) coverage regarding their clinical trials treating addiction with 18MC, and ADHD with LSD microdoses. The start dates for these phase 2a trials have been postponed until the third quarter of 2021, and have not yet started.

    MindMed is the leader in psychedelic medicines, and is my top Psychedelic Stock. Is MindMed a buy? Is MindMed a good Investment? Watch our channel to find out!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF

  • More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

    Listen, Videos

    Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)

    Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.

    We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
    So in this episode we are briefly going to run through them.

    So what else can MindMed and MMED/MMEDF investors expect this year?

    1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
    -When will it launch?
    -In what manner will it affect MindMed
    -And how much it will influence MindMed’s stock price

    2. Atai Life Sciences expected IPO how that’ll affect MindMed
    – How will the IPO of another big rival will affect MMED/MMEDF?

    3. Potential catalyst of Partnerships, Mergers and Acquisitions
    -Coming directly from an Interview with JR Rahn and Kevin O’Leary

    Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #MMED #MMEDF